ArticleDrug safety2026
Phloroglucinol Exposure During Early Pregnancy and Risk of Major Congenital Malformations: A Nationwide Cohort Study in France.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPhloroglucinol is a spasmolytic drug widely prescribed in France for gastrointestinal or pelvic pain, and frequently used during pregnancy despite limited evidence regarding its safety. We aimed to evaluate the association between first-trimester phloroglucinol exposure and the risk of major congenital malformations (MCMs) in a nationwide cohort.
methodsUsing data from the French EPI-MERES cohort based on the national health data system (SNDS), we identified all pregnancies ending after 22 weeks between 2010 and 2022, excluding women with phloroglucinol use in the year before pregnancy. We compared the risks of 68 MCM subtypes according to exposure during gestational weeks 3-12. Adjusted odds ratios (aORs) were estimated using logistic regression controlling for maternal sociodemographic, medical and pregnancy characteristics. Interpretation relied on effect size (aOR > 1.30) and consistency across sensitivity analyses.
resultsAmong 6,233,539 pregnancies, 1,024,369 (16.4%) were exposed to phloroglucinol. There were 19,635 MCM cases among children exposed to phloroglucinol and 91,693 among those unexposed (overall aOR 1.05, 95% CI 1.04-1.07). Six rare malformations showed isolated elevated risk estimates: tricuspid stenosis (aOR 1.37, 95% CI 0.96-1.94), Ebstein anomaly (aOR 1.43, 95% CI 0.99-2.06), double outlet left ventricle (aOR 1.60, 95% CI 0.83-3.09), indeterminate sex and pseudohermaphroditism (aOR 1.32, 95% CI 1.05-1.66), anencephaly and similar malformations (aOR 1.55, 95% CI 0.95-2.52), and arhinencephaly/holoprosencephaly (aOR 1.90, 95% CI: 0.97-3.72). However, these findings were not consistent across sensitivity analyses.
conclusionsIn this large nationwide cohort, first-trimester exposure to phloroglucinol was not associated with a clinically meaningful increase in the risk of major congenital malformations.
Identifiers
42593712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.